New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

EXKIVITY (mobocertinib) capsules

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

INDICATIONS AND USAGE
Exkivity (mobocertinib) is a medication used with other medicines to treat adults with locally advanced or metastatic EGFR Exon20 Insertion+ Non-Small Cell Lung Cancer (NSCLC).
DOSAGE FORMS & STRENGTHS: Capsule 40 mg
Manufactured By: Takeda Pharma A/S
Prescribing Information URL: Click Here

EXKIVITY (mobocertinib) capsules, a FDA approved prescription medicine can be accessed in India and other part of countries. South Delhi Pharma can facilitate the supply on request under Named Patient Program by fulfilling the legal requirement (if applicable) on behalf patient. Share your mobile number and email ID to get “mobocertinib tablets” cost price in India.

Category
Category

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

Medical Uses of mobocertinib capsules

Mobocertinib is indicated for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Mobocertinib, is used for the treatment of non-small cell lung cancer. Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region. Mobocertinib is an irreversible kinase inhibitor, forming a covalent bond with the cysteine 797 in the EGFR active site, leading to sustained inhibition of EGFR enzymatic activity. The irreversible binding leads to increased potency via higher affinity binding, more sustained EGFR kinase activity inhibition, and greater overall selectivity, as only a limited number of other kinases possess a cysteine in the equivalent position.

Mobocertinib was approved for medical use in the United States in September 2021. It is a first-in-class oral treatment to target EGFR Exon20 insertion mutations.

Get Access To EXKIVITY (mobocertinib) capsules In India

Brand Name “EXKIVITY (mobocertinib) capsules” or Generic Name “mobocertinib capsules” can be imported for personal use under “Named Patient Program” treatment in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. Contact us at support@southdelhipharma.com, southdelhipharma@gmail.com or call/WhatsApp at +91-9891296838 to get access as per norms.

Related Products